Avoid common mistakes on your manuscript.
Correction to: Current Cardiology Reports (2020) 22:106
On page 2 of the original publication, in the section on TTR Silencers, dosing of patisiran in the APOLLO study was stated as being given every 3 months; this is inaccurate as patisiran was dosed every 3 weeks in the APOLLO study. The corrected sentence is presented below:
“Patisiran, as an intravenous infusion every 3 weeks, also slowed functional decline versus placebo in the APOLLO study; however, in contrast to inotersen, 56% of patients had an improvement in functional outcomes from baseline [14].”
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s11886-020-01374-2
Rights and permissions
About this article
Cite this article
Hough, A., Wearden, J., de Almeida, K. et al. Correction to: Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid. Curr Cardiol Rep 22, 152 (2020). https://doi.org/10.1007/s11886-020-01426-7
Published:
DOI: https://doi.org/10.1007/s11886-020-01426-7